DEFINITIVE CONTRACT
Active75F40126C00097
Department of Health and Human Services › Food and Drug Administration › FDA OFFICE OF ACQ GRANT SVCS
$499.9K
obligated · signed 3 weeks ago
BAA FY26C1CP41: ROBUST CLINICAL ENDPOINT BIOEQUIVALENCE STUDIES USING MODEL INTEGRATED EVALUATION APPROACHES
Performance timeline
Start
Sep 1, 2026
End
Aug 31, 2028
with all options
Loading status
Estimated start: Aug 31, 2027
UPPSALA UNIVERSITET
Contract 75F40126C00097
UEI
KTRDK57SR316
Parent Company
UPPSALA UNIVERSITET
Capabilities & Certifications
Headquarters Location
Current Obligation
$499,922
Base + Exercised Options
$499,922
Total Ceiling Value
$499,922
Contract Type
FIRM FIXED PRICE
Multi-Year Contract
NO
NAICS
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
PSC
GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH
Awarding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Funding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Solicitation procedures, competition exceptions, labor standards and account totals.